Abstract
The stereospecificity shown by a wide variety of inhibitors that are effective for carboxypeptidase A (CPA), a representative zinc protease is analyzed on the basis of inhibitor type. In cases of ground state analog inhibitors and transition state analog inhibitors, the stereoisomers having the stereochemistry that corresponds to stereochemistry of substrate are more potent, but in the case of irreversible inhibitors including mechanism-based inactivators the preferred inhibitory stereochemistry cannot be predicted simply from the substrate stereospecificity. The Ogston three point fit concept may be of great value in understanding the inhibitory stereochemistry of reversible competitive inhibitors. On the other hand, the stereochemistry of irreversible inhibitors may possibly be predicted on the ground of the transition state structure that plays a critical role in the inactivation pathway.
Keywords: Metalloprotease Inhibition, carboxypeptidase A (CPA), SUBSTRATE ANALOG INHIBITORS, Thermolysin Inhibitors
Mini-Reviews in Medicinal Chemistry
Title: Origin of Chiral Pharmacology Stereochemistry in Metalloprotease Inhibition
Volume: 1 Issue: 2
Author(s): D. H. Kim
Affiliation:
Keywords: Metalloprotease Inhibition, carboxypeptidase A (CPA), SUBSTRATE ANALOG INHIBITORS, Thermolysin Inhibitors
Abstract: The stereospecificity shown by a wide variety of inhibitors that are effective for carboxypeptidase A (CPA), a representative zinc protease is analyzed on the basis of inhibitor type. In cases of ground state analog inhibitors and transition state analog inhibitors, the stereoisomers having the stereochemistry that corresponds to stereochemistry of substrate are more potent, but in the case of irreversible inhibitors including mechanism-based inactivators the preferred inhibitory stereochemistry cannot be predicted simply from the substrate stereospecificity. The Ogston three point fit concept may be of great value in understanding the inhibitory stereochemistry of reversible competitive inhibitors. On the other hand, the stereochemistry of irreversible inhibitors may possibly be predicted on the ground of the transition state structure that plays a critical role in the inactivation pathway.
Export Options
About this article
Cite this article as:
Kim H. D., Origin of Chiral Pharmacology Stereochemistry in Metalloprotease Inhibition, Mini-Reviews in Medicinal Chemistry 2001; 1 (2) . https://dx.doi.org/10.2174/1389557013407016
DOI https://dx.doi.org/10.2174/1389557013407016 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Central-To-Peripheral Arterial Stiffness Gradient in Hemodialyzed Patients Depends on the Location of the Upper-limb Vascular Access
Current Hypertension Reviews Editorial (Thematic Issue: New Therapeutic Targets in Clinical Medicine)
Current Pharmaceutical Design Age-Related Changes and Effects of Mild Hypothermia on Carotid Artery Reactivity in Newborn Rats
CNS & Neurological Disorders - Drug Targets Pro Atrial Natriuretic Peptide (1-30) and 6-keto PGF<sub>1α</sub> Activity Affects Na<sup>+</sup> Homeostasis in Non-modulating Hypertension
Current Hypertension Reviews Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature
Current Pharmaceutical Design Recent Studies of Antioxidant Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives
Current Topics in Medicinal Chemistry Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase- II in Vasoactive Peptide- Induced Responses and Vascular Biology
Current Vascular Pharmacology Body Mass Index, Lipid Metabolism and Estrogens: Their Impact on Coronary Heart Disease
Current Medicinal Chemistry Lipid-lowering Drug Therapy in Elderly Patients
Current Pharmaceutical Design The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research In Vitro Antioxidant, Antithrombotic, Antiatherogenic and Antidiabetic Activities of Urtica dioica, Sideritis euboea and Cistus creticus Water Extracts and Investigation of Pasta Fortification with the Most Bioactive One
Current Pharmaceutical Biotechnology Non-Alcoholic Fatty Liver Disease in HIV Infection Associated with Altered Hepatic Fatty Acid Composition
Current HIV Research Biochemical and Clinical Aspects of the Human Flavin-Containing Monooxygenase Form 3 (FMO3) Related to Trimethylaminuria
Current Drug Metabolism A New Antihypertensive Agent that Antagonizes the Prohypertensive Effect of Endogenous Ouabain and Adducin
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug Repositioning Through Network Pharmacology
Current Topics in Medicinal Chemistry The Fetal Cardiac Function
Current Cardiology Reviews Fluorescent Probes for Cellular Assays
Combinatorial Chemistry & High Throughput Screening Adrenomedullins: Therapeutic Potential in Cardiovascular Disease
Current Hypertension Reviews